806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications

Anti-obesity GLP-1 agonists have widely been used by providers without emphasis on behavioral modification due to the short term effectiveness of these medications. The misuse of these medications without any monitored guidance on lifestyle changes can lead to significant weight regain. In this stud...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73, p.1
Hauptverfasser: Zakaria, Hala, Caccelli, Milena, Ozkan, Cigdem, Jaafar, Zeinab, Said, Yousef, Aleabova, Sofia, Laborte, Remie Irene A, Hashemi, Ali, Almarzooqi, Ihsan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1
container_title Diabetes (New York, N.Y.)
container_volume 73
creator Zakaria, Hala
Caccelli, Milena
Ozkan, Cigdem
Jaafar, Zeinab
Said, Yousef
Aleabova, Sofia
Laborte, Remie Irene A
Hashemi, Ali
Almarzooqi, Ihsan
description Anti-obesity GLP-1 agonists have widely been used by providers without emphasis on behavioral modification due to the short term effectiveness of these medications. The misuse of these medications without any monitored guidance on lifestyle changes can lead to significant weight regain. In this study, we will evaluate newer hybrid care models involving continuous engagement by multidisciplinary care teams on weight loss among those with pre-diabetes.This is a retrospective observational study of medical records for Zone.Health, a 6 months hybrid medicated obesity program, prescribed with both GLP-1 medications and multidimensional lifestyle modification (n=112). Behavioral change aspects of the program, delivered digitally via an app, included an accountability coach, use of food logging, CGM, and involvement of a personal trainer. Anthropometric data were recorded at the beginning and at 3 months. Majority received tirzepatide (51.8%), followed by semaglutide (46.4%), and a 1.8% received liraglutide. 3 months through the program, a significant -7.89 kg (-8.24%) weight loss (p < 0.001) led to a 2.79-unit BMI decrease, including reduced fat mass (5.46 kg, p < 0.001), improved cholesterol, LDL cholesterol, and triglycerides. In pre-diabetic patients (n=33) significant improvements in HbA1c of 0.46% (p < 0.001) were observed leading to remission of all pre-diabetic patients. Weight loss was substantial at -6.85 kg (-6.8%) (p < 0.001), with reductions in fat mass (-5.26 kg, -12.5% p < 0.001). Total cholesterol levels decreased by -16.08 mg/dL (-8.3%) (p = 0.005). The hybrid program resulted in a 16.2% more reduction in weight compared to STEP-2 trial results which involved in-clinic only behavioral change advice.The use of GLP-1 medications delivered in a hybrid mode, demonstrated significant positive changes across all parameters, suggesting the potential of this approach for managing obesity and pre-diabetes using GLPs for more effective changes.
doi_str_mv 10.2337/db24-806-P
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_3111274324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111274324</sourcerecordid><originalsourceid>FETCH-proquest_journals_31112743243</originalsourceid><addsrcrecordid>eNqNis1KAzEURoMoOFY3PsGFrlPzMzSO21LtouIsWuquZDo30xRNNDcV-vYN4gPIt_jgnMPYvRQTpbV56DtV80cx5e0Fq2SjG66Veb9klRBScWkac81uiA5CiGlZxfa_8RPMncNd9j8YkAiiAwuLU5d8Dxv0wz7DMhbepjgk-wkuJnjrkHw-gQ194dh722FGgjX5MMDLsuUSXgve2exjoFt25ewH4d3fj9j4eb6aLfhXit9HpLw9xGMKRW21lFKZWqta_686AwzRSuk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111274324</pqid></control><display><type>article</type><title>806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Zakaria, Hala ; Caccelli, Milena ; Ozkan, Cigdem ; Jaafar, Zeinab ; Said, Yousef ; Aleabova, Sofia ; Laborte, Remie Irene A ; Hashemi, Ali ; Almarzooqi, Ihsan</creator><creatorcontrib>Zakaria, Hala ; Caccelli, Milena ; Ozkan, Cigdem ; Jaafar, Zeinab ; Said, Yousef ; Aleabova, Sofia ; Laborte, Remie Irene A ; Hashemi, Ali ; Almarzooqi, Ihsan</creatorcontrib><description>Anti-obesity GLP-1 agonists have widely been used by providers without emphasis on behavioral modification due to the short term effectiveness of these medications. The misuse of these medications without any monitored guidance on lifestyle changes can lead to significant weight regain. In this study, we will evaluate newer hybrid care models involving continuous engagement by multidisciplinary care teams on weight loss among those with pre-diabetes.This is a retrospective observational study of medical records for Zone.Health, a 6 months hybrid medicated obesity program, prescribed with both GLP-1 medications and multidimensional lifestyle modification (n=112). Behavioral change aspects of the program, delivered digitally via an app, included an accountability coach, use of food logging, CGM, and involvement of a personal trainer. Anthropometric data were recorded at the beginning and at 3 months. Majority received tirzepatide (51.8%), followed by semaglutide (46.4%), and a 1.8% received liraglutide. 3 months through the program, a significant -7.89 kg (-8.24%) weight loss (p &lt; 0.001) led to a 2.79-unit BMI decrease, including reduced fat mass (5.46 kg, p &lt; 0.001), improved cholesterol, LDL cholesterol, and triglycerides. In pre-diabetic patients (n=33) significant improvements in HbA1c of 0.46% (p &lt; 0.001) were observed leading to remission of all pre-diabetic patients. Weight loss was substantial at -6.85 kg (-6.8%) (p &lt; 0.001), with reductions in fat mass (-5.26 kg, -12.5% p &lt; 0.001). Total cholesterol levels decreased by -16.08 mg/dL (-8.3%) (p = 0.005). The hybrid program resulted in a 16.2% more reduction in weight compared to STEP-2 trial results which involved in-clinic only behavioral change advice.The use of GLP-1 medications delivered in a hybrid mode, demonstrated significant positive changes across all parameters, suggesting the potential of this approach for managing obesity and pre-diabetes using GLPs for more effective changes.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-806-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Body fat ; Body weight loss ; Cholesterol ; Diabetes ; Diabetes mellitus ; GLP-1 receptor agonists ; Low density lipoprotein ; Medical records ; Obesity ; Remission ; Triglycerides ; Weight control</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Zakaria, Hala</creatorcontrib><creatorcontrib>Caccelli, Milena</creatorcontrib><creatorcontrib>Ozkan, Cigdem</creatorcontrib><creatorcontrib>Jaafar, Zeinab</creatorcontrib><creatorcontrib>Said, Yousef</creatorcontrib><creatorcontrib>Aleabova, Sofia</creatorcontrib><creatorcontrib>Laborte, Remie Irene A</creatorcontrib><creatorcontrib>Hashemi, Ali</creatorcontrib><creatorcontrib>Almarzooqi, Ihsan</creatorcontrib><title>806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications</title><title>Diabetes (New York, N.Y.)</title><description>Anti-obesity GLP-1 agonists have widely been used by providers without emphasis on behavioral modification due to the short term effectiveness of these medications. The misuse of these medications without any monitored guidance on lifestyle changes can lead to significant weight regain. In this study, we will evaluate newer hybrid care models involving continuous engagement by multidisciplinary care teams on weight loss among those with pre-diabetes.This is a retrospective observational study of medical records for Zone.Health, a 6 months hybrid medicated obesity program, prescribed with both GLP-1 medications and multidimensional lifestyle modification (n=112). Behavioral change aspects of the program, delivered digitally via an app, included an accountability coach, use of food logging, CGM, and involvement of a personal trainer. Anthropometric data were recorded at the beginning and at 3 months. Majority received tirzepatide (51.8%), followed by semaglutide (46.4%), and a 1.8% received liraglutide. 3 months through the program, a significant -7.89 kg (-8.24%) weight loss (p &lt; 0.001) led to a 2.79-unit BMI decrease, including reduced fat mass (5.46 kg, p &lt; 0.001), improved cholesterol, LDL cholesterol, and triglycerides. In pre-diabetic patients (n=33) significant improvements in HbA1c of 0.46% (p &lt; 0.001) were observed leading to remission of all pre-diabetic patients. Weight loss was substantial at -6.85 kg (-6.8%) (p &lt; 0.001), with reductions in fat mass (-5.26 kg, -12.5% p &lt; 0.001). Total cholesterol levels decreased by -16.08 mg/dL (-8.3%) (p = 0.005). The hybrid program resulted in a 16.2% more reduction in weight compared to STEP-2 trial results which involved in-clinic only behavioral change advice.The use of GLP-1 medications delivered in a hybrid mode, demonstrated significant positive changes across all parameters, suggesting the potential of this approach for managing obesity and pre-diabetes using GLPs for more effective changes.</description><subject>Body fat</subject><subject>Body weight loss</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>GLP-1 receptor agonists</subject><subject>Low density lipoprotein</subject><subject>Medical records</subject><subject>Obesity</subject><subject>Remission</subject><subject>Triglycerides</subject><subject>Weight control</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNis1KAzEURoMoOFY3PsGFrlPzMzSO21LtouIsWuquZDo30xRNNDcV-vYN4gPIt_jgnMPYvRQTpbV56DtV80cx5e0Fq2SjG66Veb9klRBScWkac81uiA5CiGlZxfa_8RPMncNd9j8YkAiiAwuLU5d8Dxv0wz7DMhbepjgk-wkuJnjrkHw-gQ194dh722FGgjX5MMDLsuUSXgve2exjoFt25ewH4d3fj9j4eb6aLfhXit9HpLw9xGMKRW21lFKZWqta_686AwzRSuk</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Zakaria, Hala</creator><creator>Caccelli, Milena</creator><creator>Ozkan, Cigdem</creator><creator>Jaafar, Zeinab</creator><creator>Said, Yousef</creator><creator>Aleabova, Sofia</creator><creator>Laborte, Remie Irene A</creator><creator>Hashemi, Ali</creator><creator>Almarzooqi, Ihsan</creator><general>American Diabetes Association</general><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240601</creationdate><title>806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications</title><author>Zakaria, Hala ; Caccelli, Milena ; Ozkan, Cigdem ; Jaafar, Zeinab ; Said, Yousef ; Aleabova, Sofia ; Laborte, Remie Irene A ; Hashemi, Ali ; Almarzooqi, Ihsan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_31112743243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Body fat</topic><topic>Body weight loss</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>GLP-1 receptor agonists</topic><topic>Low density lipoprotein</topic><topic>Medical records</topic><topic>Obesity</topic><topic>Remission</topic><topic>Triglycerides</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zakaria, Hala</creatorcontrib><creatorcontrib>Caccelli, Milena</creatorcontrib><creatorcontrib>Ozkan, Cigdem</creatorcontrib><creatorcontrib>Jaafar, Zeinab</creatorcontrib><creatorcontrib>Said, Yousef</creatorcontrib><creatorcontrib>Aleabova, Sofia</creatorcontrib><creatorcontrib>Laborte, Remie Irene A</creatorcontrib><creatorcontrib>Hashemi, Ali</creatorcontrib><creatorcontrib>Almarzooqi, Ihsan</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zakaria, Hala</au><au>Caccelli, Milena</au><au>Ozkan, Cigdem</au><au>Jaafar, Zeinab</au><au>Said, Yousef</au><au>Aleabova, Sofia</au><au>Laborte, Remie Irene A</au><au>Hashemi, Ali</au><au>Almarzooqi, Ihsan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-01</date><risdate>2024</risdate><volume>73</volume><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Anti-obesity GLP-1 agonists have widely been used by providers without emphasis on behavioral modification due to the short term effectiveness of these medications. The misuse of these medications without any monitored guidance on lifestyle changes can lead to significant weight regain. In this study, we will evaluate newer hybrid care models involving continuous engagement by multidisciplinary care teams on weight loss among those with pre-diabetes.This is a retrospective observational study of medical records for Zone.Health, a 6 months hybrid medicated obesity program, prescribed with both GLP-1 medications and multidimensional lifestyle modification (n=112). Behavioral change aspects of the program, delivered digitally via an app, included an accountability coach, use of food logging, CGM, and involvement of a personal trainer. Anthropometric data were recorded at the beginning and at 3 months. Majority received tirzepatide (51.8%), followed by semaglutide (46.4%), and a 1.8% received liraglutide. 3 months through the program, a significant -7.89 kg (-8.24%) weight loss (p &lt; 0.001) led to a 2.79-unit BMI decrease, including reduced fat mass (5.46 kg, p &lt; 0.001), improved cholesterol, LDL cholesterol, and triglycerides. In pre-diabetic patients (n=33) significant improvements in HbA1c of 0.46% (p &lt; 0.001) were observed leading to remission of all pre-diabetic patients. Weight loss was substantial at -6.85 kg (-6.8%) (p &lt; 0.001), with reductions in fat mass (-5.26 kg, -12.5% p &lt; 0.001). Total cholesterol levels decreased by -16.08 mg/dL (-8.3%) (p = 0.005). The hybrid program resulted in a 16.2% more reduction in weight compared to STEP-2 trial results which involved in-clinic only behavioral change advice.The use of GLP-1 medications delivered in a hybrid mode, demonstrated significant positive changes across all parameters, suggesting the potential of this approach for managing obesity and pre-diabetes using GLPs for more effective changes.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-806-P</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1
issn 0012-1797
1939-327X
language eng
recordid cdi_proquest_journals_3111274324
source EZB-FREE-00999 freely available EZB journals
subjects Body fat
Body weight loss
Cholesterol
Diabetes
Diabetes mellitus
GLP-1 receptor agonists
Low density lipoprotein
Medical records
Obesity
Remission
Triglycerides
Weight control
title 806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A34%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=806-P:%20Effectiveness%20of%20a%20Hybrid%20Weight%20Loss%20Program%20for%20Obesity%20and%20Prediabetes%20Using%20GLP-1%20Medications&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=Zakaria,%20Hala&rft.date=2024-06-01&rft.volume=73&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-806-P&rft_dat=%3Cproquest%3E3111274324%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111274324&rft_id=info:pmid/&rfr_iscdi=true